BeStock  
Stocks › Biotechnology › URGN

UroGen Pharma Ltd URGN

US equityMarket cap rank #2953Biotechnology
$27.65 −$4.08 (-12.86%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $27.65 0.00%
Open$31.15
Prev close$31.73
Day range$27.57 – $31.90
Volume2.40M
Market cap$1.36B
P/E (TTM)–
Dividend yield–

Valuation

Multiples measured against the stock's own five-year history

Price / earnings-20.0x
CheapRich

Near the bottom of its 5-year range · 4th percentile, 5-year average -4.9x

Price / book-10.3x
CheapRich

Below its usual level · 31st percentile, 5-year average -5.5x

Price / sales5.1x
CheapRich

Below its usual level · 39th percentile, 5-year average 6.4x

#3963 of 5155 stocks by PS (1 = cheapest)

P/E over five years

-26x-17x-7x2xOct '21Apr '24Nov '26

Dashed line is the 5-year average; the shaded band is one standard deviation either side.

Morningstar fair value estimate

Fair value$28.54
Price vs. fair value-3.1%Close to the estimate
Star rating★★★☆☆
Economic moatNone
UncertaintyVery High
MultipleCurrentForward5y averagePercentile vs. own historyIndustry rank
PB -10.25 – -5.46 31% (cheaper than usual) –
PE -19.98 10.14 -4.94 4% (cheaper than usual) –
PS 5.13 2.64 6.43 39% (cheaper than usual) #3963 of 5155 (1 = cheapest)

Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.

Discussion

No comments yet — be the first to weigh in on URGN.

Sign in to join the discussion.

Scroll to Top